On January 28, 2020 Stand Up To Cancer (SU2C) reported that it has awarded the 2020 Laura Ziskin Prize in Translational Research to two highly respected clinical investigators who will come together in a novel collaboration between leaders in breast cancer immuno-oncology and tumor immunology for research to further the availability of immune checkpoint inhibitors for breast cancer patients (Press release, SU2C, JAN 28, 2020, View Source [SID1234553614]). Dr. Leisha A. Emens, MD, PhD of UPMC Hillman Cancer Center, and Dr. Xiang Zhang, PhD of Baylor College of Medicine will share a $250,000 grant for their year-long research project which was awarded today at the 2020 SU2C Scientific Summit in Santa Monica.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Ziskin Prize is named after legendary Hollywood producer and Stand Up To Cancer Co-Founder Laura Ziskin, who lived with breast cancer for seven years before it took her life in 2011. Inaugurated in 2012, the prize was created with $1.1 million for this purpose in Ziskin’s will and has been awarded in 2012, 2014, 2015, 2018 and 2019.
"With their diverse backgrounds and complementary expertise, we’re confident that these two investigators will make great contributions to further develop therapies that could provide improved outcomes for breast cancer patients – and potentially reduce mortality rates," said Selection Committee co-chair John Glaspy, MD, MPH, professor. In granting the award, Selection Committee members included: co-chair Stephen Baylin, PhD, Johns Hopkins School of Medicine; Lewis Cantley, PhD, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College/Ronald P. Stanton Clinical Cancer Program at New York-Presbyterian; Gordon Mills, MD, PhD, OHSU Knight Cancer Institute; Carlos Arteaga, MD, Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center; Ingrid Mayer, MD, MSCI, Vanderbilt University; Nancy Davidson, MD, Fred Hutchinson Cancer Research Center; Dennis Slamon, MD, PhD, Chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA’s Department of Medicine; and Matthew Ellis, MB, BChir, BSc, PhD, FRCP, Baylor College of Medicine.
Dr. Emens is a professor of medicine in hematology/oncology, co-leader of the Hillman Cancer Immunology and Immunotherapy Program, and director of translational immunotherapy for the Women’s Cancer Research Center (WCRC) at UPMC. She is internationally recognized for her work in breast cancer immunotherapy. Clinically, she has developed a vaccine for breast cancer patients, and most recently led the development of atezolizumab from preclinical evaluation in human breast tumors to Phase 1 and Phase 3 clinical trials, resulting in an FDA approval for advanced triple negative breast cancer.
Dr. Zhang is a professor at the Baylor College of Medicine Breast Center whose research focuses on metastatic breast cancer where he has made significant contributions to the field. In the area of bone metastasis, he discovered the osteogenic niche that promotes early-stage bone colonization and invented a series of pre-clinical models and technologies to accelerate anti-metastasis drug discovery. In the area of tumor immunology and immunotherapies, he has made significant discoveries regarding the tumor microenvironment and its responses to checkpoint blockade therapies and has given a new understanding of how these interactions can affect the therapies.